Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) |
Viread is owned by Gilead Sciences Inc.
Viread contains Tenofovir Disoproxil Fumarate.
Viread has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Viread are:
Viread was authorised for market use on 18 January, 2012.
Viread is available in tablet;oral, powder;oral dosage forms.
Viread can be used as treatment of hiv infection in combination with one or more additional hiv antiviral agents, treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older, treatment of hiv.
The generics of Viread are possible to be released after 25 January, 2018.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-569) | Aug 11, 2011 |
M(M-128) | Jul 24, 2016 |
M(M-95) | Oct 01, 2013 |
Pediatric Exclusivity(PED) | Apr 01, 2014 |
New Patient Population(NPP) | Aug 16, 2015 |
Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Treatment: Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older; Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hi...
Dosage: TABLET;ORAL; POWDER;ORAL